Most notably, we identify a deletion (Fig S6a) and translocation (causing eQTL gains) affecting TP53 in prostate cancer, and an inversion (Fig S6b) and translocation causing ERBB2 to gain eQTLs and a (super) enhancer in ovarian cancer. This evidence concerns the gene ERBB2 and ovarian carcinoma.